138 related articles for article (PubMed ID: 7909916)
1. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens.
Vineis P; Bartsch H; Caporaso N; Harrington AM; Kadlubar FF; Landi MT; Malaveille C; Shields PG; Skipper P; Talaska G
Nature; 1994 May; 369(6476):154-6. PubMed ID: 7909916
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels.
Landi MT; Zocchetti C; Bernucci I; Kadlubar FF; Tannenbaum S; Skipper P; Bartsch H; Malaveille C; Shields P; Caporaso NE; Vineis P
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):693-8. PubMed ID: 8877060
[TBL] [Abstract][Full Text] [Related]
3. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
[TBL] [Abstract][Full Text] [Related]
4. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
[TBL] [Abstract][Full Text] [Related]
5. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
[TBL] [Abstract][Full Text] [Related]
6. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens.
Hein DW; Doll MA; Rustan TD; Gray K; Ferguson RJ; Feng Y
Toxicol Appl Pharmacol; 1994 Jan; 124(1):16-24. PubMed ID: 8291057
[TBL] [Abstract][Full Text] [Related]
7. Extrahepatic expression of the N-acetylation polymorphism toward arylamine carcinogens in tumor target organs of an inbred rat model.
Hein DW; Rustan TD; Bucher KD; Furman EJ; Martin WJ
J Pharmacol Exp Ther; 1991 Jul; 258(1):232-6. PubMed ID: 2072298
[TBL] [Abstract][Full Text] [Related]
8. Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking.
Vineis P; Caporaso N; Tannenbaum SR; Skipper PL; Glogowski J; Bartsch H; Coda M; Talaska G; Kadlubar F
Cancer Res; 1990 May; 50(10):3002-4. PubMed ID: 2334904
[TBL] [Abstract][Full Text] [Related]
9. Polymorphic and monomorphic expression of arylamine carcinogen N-acetyltransferase isozymes in tumor target organ cytosols of Syrian hamsters congenic at the polymorphic acetyltransferase locus.
Hein DW; Rustan TD; Bucher KD; Miller LS
J Pharmacol Exp Ther; 1991 Nov; 259(2):699-704. PubMed ID: 1941618
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility.
Badawi AF; Stern SJ; Lang NP; Kadlubar FF
Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986
[TBL] [Abstract][Full Text] [Related]
11. Assessment of exposure and susceptibility to aromatic amine carcinogens.
Kadlubar FF; Talaska G; Lang NP; Benson RW; Roberts DW
IARC Sci Publ; 1988; (89):166-74. PubMed ID: 3198199
[TBL] [Abstract][Full Text] [Related]
12. Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens.
Fretland AJ; Doll MA; Gray K; Feng Y; Hein DW
Toxicol Appl Pharmacol; 1997 Feb; 142(2):360-6. PubMed ID: 9070359
[TBL] [Abstract][Full Text] [Related]
13. Molecular epidemiology of bladder cancer.
Vineis P; Martone T
Ann Ist Super Sanita; 1996; 32(1):21-7. PubMed ID: 8967722
[TBL] [Abstract][Full Text] [Related]
14. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
15. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.
Grant DM; Mörike K; Eichelbaum M; Meyer UA
J Clin Invest; 1990 Mar; 85(3):968-72. PubMed ID: 2312737
[TBL] [Abstract][Full Text] [Related]
16. Polymorphic NATs and cancer predisposition.
Hirvonen A
IARC Sci Publ; 1999; (148):251-70. PubMed ID: 10493262
[TBL] [Abstract][Full Text] [Related]
17. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.
Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381
[TBL] [Abstract][Full Text] [Related]
18. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus.
Kaufmann GR; Wenk M; Taeschner W; Peterli B; Gyr K; Meyer UA; Haefeli WE
Clin Pharmacol Ther; 1996 Jul; 60(1):62-7. PubMed ID: 8689813
[TBL] [Abstract][Full Text] [Related]
19. Cloning, expression, and functional characterization of two mutant (NAT2(191) and NAT2(341/803)) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles.
Ferguson RJ; Doll MA; Rustan TD; Gray K; Hein DW
Drug Metab Dispos; 1994; 22(3):371-6. PubMed ID: 7915226
[TBL] [Abstract][Full Text] [Related]
20. Acetylator status, drug metabolism and disease.
Pande JN; Pande A; Singh SP
Natl Med J India; 2003; 16(1):24-6. PubMed ID: 12715953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
